Ordopidine

Ordopidine
Clinical data
Other namesACR325; ACR-325
Routes of
administration		Oral[1]
Drug classAtypical dopamine D2 receptor antagonist; Dopaminergic stabilizer
ATC code
  • None
Identifiers
  • 1-ethyl-4-(2-fluoro-3-methylsulfonylphenyl)piperidine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20FNO2S
Molar mass285.38 g·mol−1
3D model (JSmol)
  • CCN1CCC(CC1)C2=C(C(=CC=C2)S(=O)(=O)C)F
  • InChI=1S/C14H20FNO2S/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18/h4-6,11H,3,7-10H2,1-2H3
  • Key:UKUPJASJNQDHPH-UHFFFAOYSA-N

Ordopidine (INNTooltip International Nonproprietary Name; developmental code ACR-325) is an atypical dopamine D2 receptor antagonist and so-called "dopaminergic stabilizer" which is or was under development for the treatment of Parkinson's disease and bipolar disorder.[1][2][3][4] It is taken orally.[1]

The drug acts as a competitive low-affinity dopamine D2 receptor antagonist with a fast dissociation rate in vitro.[3][4] It inhibits dextroamphetamine-induced hyperlocomotion in rodents but has little effect on locomotor activity in untreated animals and stimulates behavioral activity in states of hypoactivity.[3][4] This state-dependent profile of behavioral effects is not shared with other dopamine D2 receptor antagonists.[3][4] Ordopidine shows similar neurochemical effects as conventional dopamine D2 receptor antagonists, such as increased dopamine and/or dopamine metabolite levels in various brain areas like the frontal cortex, basal ganglia, and limbic system.[3][4]

The actions and effects of ordopidine are similar to those of its close analogue pridopidine (which it differs from only by a single methyl group).[3] Subsequent to their initial characterization, pridopidine was found to act as a sigma receptor ligand with much higher affinity than for the dopamine D2 receptor, with this balance of activities potentially explaining its atypicality and "dopaminergic stabilizer" properties.[5]

Ordopidine was first described in the scientific literature by 2009.[4] The drug was developed by Carlsson Research, NeuroSearch Sweden, and Saniona.[1][2] As of June 2019, no recent development has been reported.[1][2] Ordopidine has reached phase 1 clinical trials.[1][2]

See also

References

  1. ^ a b c d e f "Ordopidine". AdisInsight. 28 June 2019. Retrieved 31 January 2026.
  2. ^ a b c d "Delving into the Latest Updates on Ordopidine with Synapse". Synapse. 31 January 2026. Retrieved 1 February 2026.
  3. ^ a b c d e f Waters S, Ponten H, Edling M, Svanberg B, Klamer D, Waters N (November 2014). "The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression". Journal of Neural Transmission. 121 (11): 1337–1347. doi:10.1007/s00702-014-1231-1. PMID 24817271.
  4. ^ a b c d e f Pontón H, Dyhring T, Edling M, Pettersson F, Sonesson C, Svanberg B, et al. (2009). "P.l.c.043 ACR325: a dopaminergic stabiliser that displays state-dependent effects in-vivo". European Neuropsychopharmacology. 19: S276. doi:10.1016/S0924-977X(09)70403-1. Retrieved 1 February 2026.
  5. ^ Sahlholm K, Sijbesma JW, Maas B, Kwizera C, Marcellino D, Ramakrishnan NK, et al. (September 2015). "Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses". Psychopharmacology. 232 (18): 3443–3453. doi:10.1007/s00213-015-3997-8. PMC 4537502. PMID 26159455.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.